Recent events
Recent events tied to this brand in public sources.
Back to profile7 entries
2026
BioMarin announces acquisition of Alesta Therapeutics for $275m upfront
BioMarin Pharmaceutical announced it will acquire Alesta Therapeutics for $275 million upfront plus up to $215 million in development and regulatory milestones, bringing the clinical-stage oral hypophosphatasia candidate ALE1 into its pipeline. The deal was approved by both boards, Alesta will spin out all non-ALE1 assets to a new entity before closing, and the transaction is expected to close this quarter subject to customary closing conditions.
2021
BioMarin announces Mark Alles board appointment
BioMarin announced that Mark Alles would join its Board of Directors effective January 1, 2022.
2021
FDA approves Voxzogo for children with achondroplasia
The US Food and Drug Administration approved vosoritide, marketed as Voxzogo, for children aged 5 years and older with achondroplasia and open growth plates. The approval was under the FDA's accelerated approval pathway; BioMarin is required to conduct a postmarketing study to assess final adult height.
2021
FDA grants accelerated approval to Voxzogo
The U.S. Food and Drug Administration granted accelerated approval to BioMarin's Voxzogo to increase linear growth in pediatric patients aged five and older with achondroplasia and open epiphyses. Continued approval may depend on verification and description of clinical benefit in confirmatory studies.
2021
FDA extends vosoritide review target date
BioMarin reported that the FDA extended the PDUFA target action date for its vosoritide application by three months, to November 20, 2021, to allow review of submitted two-year Phase 3 results.
2021
BioMarin announces 2021 financial guidance
BioMarin announced financial guidance for 2021, including projected total revenues of $1.75 billion to $1.85 billion.
2020
BioMarin prices $550 million convertible notes offering
BioMarin announced the pricing of a $550 million private offering of senior subordinated convertible notes due 2027. The offering size was increased from the previously announced $500 million.